A very sad and sorry state of affairs.
Management need to boost revenues significantly over the next 12 months quarter on quarter... if they do, we'll likely be 5x the current share price. If they don't we're heading to 0.
- Forums
- ASX - By Stock
- AVR
- Admedus Trend line
Admedus Trend line, page-58
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 300 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.91 | 475 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 300 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
1 | 330 | 9.510 |
2 | 1185 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
9.910 | 475 | 2 |
9.990 | 99 | 1 |
10.000 | 250 | 1 |
10.500 | 10005 | 2 |
11.000 | 5000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online